Lilly at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

Lilly takes part in 7 sessions at ACT 2026 in San Antonio. Its program centres on reducing animal use in antibody development and on assessing drug risks to the brain and nerves. It also covers interpreting embryofetal development study data and delivering oligonucleotide drugs to nerve cells.

Organization

ACT 2026 Attendance

Lilly

Indianapolis, IN

◆Diamond Supporter

lilly.com

Pharmaceutical companiesDiamond Supporter

Global pharmaceutical company with medicines in diabetes, obesity, oncology, immunology and neuroscience.

Talk

Sun Nov 15
10:00am–10:35am

Part of The ABCs of EFDs: A Modern Guide to Embryofetal Development Testing (CE3)

Interpreting EFD Study Data (CE3-5)

DART

Talk

Sun Nov 15
10:00am–10:30am

Part of Working with Global Regulators for Streamlined Nonclinical Development (CE4)

Sponsor Strategies for Successful Regulatory Agency Interactions (CE4-5)

Regulatory

Talk

Tue Nov 17
9:50am–10:15am

Part of Overcoming the Blood-Brain Barrier and Translational Challenges in the Nonclinical Development of CNS Drugs (S08)

Nonclinical Developmental Considerations for Neuronal Delivery of Oligonucleotides (S08-4)

Biologics and new modalities · Neurotoxicology

Session

Tue Nov 17
2:00pm–5:00pm

From Policy to Practice: Progress on the FDA’s 2025 Roadmap to Reduce Animal Use in Antibody Platform Development (S12)

New approach methods · Regulatory · with Neurocrine Biosciences

2:00pmWelcome and Overview (S12-1)Neurocrine Biosciences
2:05pmA Brief History of Regulatory Efforts to Reduce Animal Use in Drug Development (S12-2)Lilly
2:20pmThe FDA Roadmap and Adoption of NAMs for Regulatory Decision Making (S12-3)U.S. Food and Drug Administration
2:50pmIndustry Experience: DruSafe/BioSafe Survey (S12-4)Agios Pharmaceuticals
3:45pmNAM Qualification Pathway for an ISTAND Drug Development Tool (S12-5)Integral Molecular

Talk

Tue Nov 17
2:05pm–2:20pm

Part of From Policy to Practice: Progress on the FDA’s 2025 Roadmap to Reduce Animal Use in Antibody Platform Development (S12)

A Brief History of Regulatory Efforts to Reduce Animal Use in Drug Development (S12-2)

Regulatory · New approach methods

Talk

Wed Nov 18
9:00am–9:10am

Part of Modernizing Drug Development: Advanced Translational Methodologies for CNS and PNS Risk Assessment (S13)

Introduction on CNS Risk Assessment (S13-1)

Neurotoxicology

Session

Wed Nov 18
9:00am–12:00pm

Modernizing Drug Development: Advanced Translational Methodologies for CNS and PNS Risk Assessment (S13)

Neurotoxicology · with Charles River

9:00amIntroduction on CNS Risk Assessment (S13-1)Lilly
9:10amNeurotoxicology in General Toxicology Studies: Interactive Case Studies to Explore Common Challenges, Regulatory Strategies, and Innovative Approaches (S13-2)Charles River
9:40amMechanistic Insights into Species-Specific Seizure Susceptibility (S13-3)ApconiX
10:45amThe Complexity of Drug Development Illustrated with Nav1.7-Associated Dysautonomia (S13-4)Genentech
11:10amCNS NAMs for modeling of neural plasticity and learning in neural organoids (S13-5)Johns Hopkins University

Instantly find 20 buyers from Lilly

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction